scholarly journals Integrating high touch specialty pharmacy services within a neurology clinic to improve medication access and affordability

2019 ◽  
Vol 8 (sup1) ◽  
pp. 24-24
Author(s):  
Brandon Newman ◽  
Amanda Hickman ◽  
Kathryn Edwards
Keyword(s):  
Pharmacy Services ◽  
Medication Access ◽  
Neurology Clinic ◽  
Specialty Pharmacy ◽  
Access And Affordability

scholarly journals Incorporation and Impact of a Clinical Pharmacist in a Hospital-Based Neurology Clinic Treating Multiple Sclerosis Patients

2020 ◽  
pp. 0000-0000
Author(s):  
Alexandria May ◽  
Olivia Morgan ◽  
Kristi Quairoli
Keyword(s):  
Patient Care ◽  
Clinical Pharmacy ◽  
Clinical Pharmacist ◽  
Medication Management ◽  
Pharmacy Services ◽  
Patient Counseling ◽  
Clinical Pharmacy Services ◽  
Clinical Pharmacists ◽  
Medication Access ◽  
Neurology Clinic

Abstract Background: Clinical pharmacists are uniquely positioned to assist with the complexities of medication management for patients with multiple sclerosis (MS). The objective of this study is to describe clinical pharmacy services provided as well as provider satisfaction and perceived impact of incorporating a clinical pharmacist in MS patient care. Methods: This study was conducted in two parts: a retrospective chart review and provider survey conducted in an outpatient neurology clinic at an academic medical center. Between April 2017 and June 2018, electronic medical records (EMRs) of patients with documented interventions by a pharmacist were reviewed to describe clinical pharmacy services provided to MS patients. A voluntary, anonymous survey was distributed to neurology providers to evaluate provider satisfaction and perceived impact of clinical pharmacist involvement in MS patient care. Results: There were 64 patients identified during the study period with 378 documented interventions made by clinical pharmacists. Pharmacist interventions were most commonly related to facilitating medication access (N=208), pre-treatment screening (N=57), patient counseling (N=51), and providing drug information (N=43). All providers surveyed (n=9) indicated that facilitating medication access, patient counseling, and drug interaction management were moderately or very important clinical pharmacy services. Furthermore, all providers surveyed strongly agreed that pharmacist involvement decreased time to therapy initiation for patients and decreased provider time spent on medication management. Conclusions: Clinical pharmacists play an integral role in MS patient care, particularly with facilitating medication access. Prospective studies are needed to further evaluate the contribution of clinical pharmacists in the care of MS patients.

scholarly journals Impact of Pharmacy Services on Time to Elexacaftor-Tezacaftor-Ivacaftor Initiation

2021 ◽  
Author(s):  
Lauren Roder ◽  
Michelle Simonsen ◽  
Lindsey Fitzpatrick ◽  
Jennifer Loucks ◽  
Jianghua He
Keyword(s):  
Cystic Fibrosis ◽  
Health System ◽  
Retrospective Chart Review ◽  
Pharmacy Services ◽  
Related Complication ◽  
Receptor Modulator ◽  
Medication Access ◽  
Fda Approval ◽  
Specialty Pharmacy ◽  
The Impact

The approval of elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) expanded highly effective cystic fibrosis transmembrane receptor modulator therapy to approximately 90% of persons age 12 and older with cystic fibrosis. Clinical pharmacists and pharmacy technicians played a key role in planning for ELX/TEZ/IVA initiation prior to FDA approval as well as initiating therapy after approval. This study evaluates the impact of pharmacy services on time to ELX/TEZ/IVA initiation. A retrospective chart review evaluated patients qualifying for ELX/TEZ/IVA at a single health system between October 21, 2019 and April 1, 2020. Patients filling ELX/TEZ/IVA at an integrated health system specialty pharmacy (HSSP) versus an outside specialty pharmacy (SP) started on therapy an average of 10.8 days faster (10.8 days ± 14.0 vs 21.6 days ± 18.8 respectively; p=0.006). More patients filling at a HSSP received ELX/TEZ/IVA within 14 days of the prescription being written compared to outside SPs (82.0% vs 41.4% respectively; p=0.001). Pre-ELX/TEZ/IVA initiation, patients were hospitalized for a CF related complication for an average of 6.26 days (range 0-183) compared to 1.16 days (range 0-91) post-ELX/TEZ/IVA initiation. Lastly, an estimated $134,810 was saved in the 105 patients that were able to fill ELX/TEZ/IVA at a HSSP by initiating drug an average of 10.8 days quicker than outside SPs. The results of this study demonstrate the value of an integrated HSSP model. Further advocacy for inclusion of integrated HSSPs by pharmacy benefit managers is needed to optimize medication access, control costs, and improve patient outcomes for patients receiving care within a health system.

scholarly journals 241: The impact of implementing specialty pharmacy services within a cystic fibrosis clinic

2021 ◽  
Vol 20 ◽  
pp. S117
Author(s):  
J. Scheper ◽  
S. Bruner ◽  
P. Flume ◽  
L. McCoy ◽  
S. Gray ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pharmacy Services ◽  
Specialty Pharmacy ◽  
The Impact

scholarly journals Anti-hypertensive medication access and affordability and their association with blood pressure control at a teaching hospital in Ghana

2021 ◽  
Vol 39 ◽  
Author(s):  
Mark Amankwa Harrison ◽  
Afia Frimpomaa Asare Marfo ◽  
Mercy Naa Aduele Opare-Addo ◽  
Daniel Nii Amoo Ankrah ◽  
Franklin Acheampong ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Teaching Hospital ◽  
Pressure Control ◽  
Medication Access ◽  
Access And Affordability

scholarly journals Specialty Pharmacy Services: Preparing for a New Era in Health-System Pharmacy

2015 ◽  
Vol 50 (9) ◽  
pp. 834-839 ◽  
Author(s):  
Blake Shay ◽  
Les Louden ◽  
Bonnie Kirschenbaum
Keyword(s):  
Health System ◽  
Pharmacy Services ◽  
New Era ◽  
Specialty Pharmacy

Specialty pharmacy services

Remington ◽  
2021 ◽  
pp. 829-836
Author(s):  
Vivianne K. Celario ◽  
Pinal Mistry
Keyword(s):  
Pharmacy Services ◽  
Specialty Pharmacy

scholarly journals Advancing Patient Care Through Specialty Pharmacy Services in an Academic Health System

2017 ◽  
Vol 23 (8) ◽  
pp. 815-820 ◽  
Author(s):  
Autumn Bagwell ◽  
Tara Kelley ◽  
Alicia Carver ◽  
Jennifer B. Lee ◽  
Brandon Newman
Keyword(s):  
Health System ◽  
Patient Care ◽  
Pharmacy Services ◽  
Academic Health ◽  
Specialty Pharmacy

Evaluation of a specialty hepatitis C virus telephone pharmacy service

2021 ◽  
Author(s):  
Ashley A Sabourin ◽  
Kaleigh K Fisher-Grant ◽  
Adam R Saulles ◽  
Rima A Mohammad
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Pharmacy Service ◽  
Hcv Infection ◽  
Pharmacy Services ◽  
Specialty Pharmacy ◽  
Clinically Significant ◽  
Direct Acting ◽  
The Impact

Abstract Purpose Direct-acting antivirals (DAAs) used to treat hepatitis C virus (HCV) infection are associated with significant drug-drug interactions (DDIs). Pharmacists are well positioned to identify and mitigate these DDIs. Data to guide assessment of the impact of HCV specialty pharmacy services on identifying and addressing DDIs with DAAs are lacking. The overall purpose of the study described here was to determine the incidence and severity of DDIs identified by specialty pharmacists among patients treated with DAAs prior to and 1 month into therapy. Methods An observational, retrospective study was conducted to evaluate the impact of specialty pharmacy services in mitigating DDIs associated with use of DAAs. Adult patients with HCV infection (n = 200) who received DAAs and were enrolled with a specialty pharmacy service over a 1-year period were included. Endpoints included number, severity, and type of DDIs and DDIs per patient at baseline and 1 month into therapy, pharmacists’ interventions, and safety and clinical outcomes. Results Fifty-nine percent of patients had at least 1 DDI. A total of 170 DDIs were identified (137 at baseline and 33 at 1-month follow-up), and the mean number of DDIs per patient significantly decreased from baseline to 1-month follow-up (from 1.38 to 0.16, P < 0.0001). The rate of “potentially clinically significant” or “critical” interactions was significantly lower at 1-month follow-up vs baseline assessment (69.6% vs 81.7%, P < 0.0001). The most commonly identified DDIs involved acid suppressive medications (49.6% and 66.6% of DDIs at baseline and follow-up assessment, respectively) and cardiovascular medications (26.2% and 21.2%, respectively). Total number of DDI interventions was 131, with an acceptance rate of 85%. Most common intervention was patient education and monitoring. Conclusion Approximately 60% of patients had DDIs with DAAs. Implementing HCV specialty pharmacy services significantly decreased DDIs while maintaining SVR12.

Sign in / Sign up

Export Citation Format

Share Document